Stock Market & Financial Investment News

News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 11:43 EDT VRTX Options with decreasing implied volatility: PVH VRTX EWG Subscribe for More Information 08:36 EDT VRTX Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. June 17, 2013 07:28 EDT VRTX Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 09:38 EDT VRTX Vertex has a conference call hosted by JPMorgan Subscribe for More Information 07:25 EDT VRTX Vertex CF data positive, says RBC Capital RBC Capital believes that data on Vertex's CF drug looked good and lowers the risk of the treatment. The firm expects the company to report good Phase III results for the drug in summer 2014, and it reiterates an Outperform rating on the stock. June 12, 2013 07:33 EDT VRTX European Cystic Fibrosis Society to host a conference 36th ECFS Conference is being held in Lisbon, Portugal on June 12-15. June 11, 2013 14:37 EDT VRTX SMC posts decision on Kalydeco resubmission to website Subscribe for More Information 07:31 EDT VRTX Goldman to host a conference Subscribe for More Information June 5, 2013 10:25 EDT VRTX Vertex says 6 abstracts from cystic fibrosis program to be presented at ECFS Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.